Monitor for shareholder vote and regulatory approvals for the reverse merger. The deal provides CYCN with a well-funded pipeline but at extreme dilution to current holders. Key catalysts include CTN filing (YE26), IND filing (1Q27), and Phase 1 data (mid-2027). The stock's historical underperformance suggests caution; watch for any opposition or deal renegotiation.
Price Chart
Executive Summary
Cyclerion Therapeutics (CYCN) filed a Korsana Biosciences investor presentation in connection with their proposed reverse merger and concurrent $380M private placement, expected to close in 3Q26. The combined company, to be renamed Korsana and trade under ticker KRSA, will focus on developing KRSA-028, a potentially best-in-class shuttled anti-amyloid beta therapy for Alzheimer's disease, with preclinical data suggesting advantages over Roche's trontinemab. Current CYCN shareholders will be diluted to approximately 1.1% ownership of the combined entity, while PIPE investors will hold ~53.4%.
Key Financial Metrics
Key Facts
- Reverse merger with Korsana Biosciences expected to close in 3Q26, with concurrent $380M PIPE
- Current CYCN shareholders to own ~1.1% of combined company; PIPE investors ~53.4%; Korsana holders ~45.5%
- Combined company expected to trade on Nasdaq as KRSA with pro-forma cash of ~$475M and runway into 2029
- Lead program KRSA-028 is a THETA-enabled anti-3pE amyloid beta mAb for Alzheimer's, currently IND-enabling
- Preclinical data shows KRSA-028 has >2.5x longer half-life in NHPs vs trontinemab and avoids reticulocyte depletion
- Phase 1/2 trial planned: SAD in healthy volunteers (data mid-2027), MAD in AD patients (data YE27-1Q28)
- Korsana CEO Jonathan Violin previously led Viridian Therapeutics, Dianthus Therapeutics, and Quellis Biosciences
Financial Impact
CYCN shareholders diluted to ~1.1% of combined company valued at implied ~$475M post-PIPE cash; $380M PIPE provides substantial non-dilutive funding for KRSA-028 development
Risk Factors
- Deal completion risk: requires shareholder approval and regulatory clearances
- Extreme dilution: current CYCN holders own only 1.1% of combined company
- Clinical risk: KRSA-028 is preclinical; Phase 1 data not expected until mid-2027
- Competition: Roche's trontinemab and Lilly's remternetug are ahead in development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (CYCN) — Batch item 1 | 0001193125-26-301054 |
| Document: 0001193125-26-301054-index-headers.html | 0001193125-26-301054 |
| Document: 0001193125-26-301054-index.html | 0001193125-26-301054 |
| Document: 0001193125-26-301054.txt | 0001193125-26-301054 |
| 425 Filing (CYCN) — Batch item 5 | 0001193125-26-301054 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 20d ago | SC 13G/A | — | awaiting T+5 | — | — |
Sep 11, 2026 6w ago | 8-K | $3.47 | awaiting T+5 | — | — |
Sep 10, 2026 6w ago | 3 | $3.47 | awaiting T+5 | — | — |
Aug 27, 2026 8w ago | 8-K | $3.99 $4.96 | ▲ +24.31% | ▲ +24.04% | — |
Aug 10, 2026 11w ago | 425 | $3.57 $4.12 | ▲ +15.41% | ▲ +15.81% | — |
Aug 3, 2026 12w ago | 425 | $3.51 $3.57 | ▲ +1.71% | ▲ +1.81% | — |
Jul 27, 2026 13w ago | EFFECT | $3.50 $3.44 | ▼ −1.71% | ▼ −2.79% | — |
Jul 10, 2026 15w ago | 425 | $3.82 $3.64 | ▼ −4.71% | ▼ −3.93% | — |
Jun 9, 2026 20w ago | S-4/A | $3.09 $3.18 | ▼ −2.91% | ▲ +0.52% | — |
Apr 30, 2026 25w ago | 10-K/A | $3.31 $3.24 | ▼ −2.11% | ▼ −3.84% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers